Project Description:
A Phase 3 study to evaluate the safety and efficacy of Lumacaftor in Combination with Ivacaftor in subjects aged 12 years and above.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals
Unserved or Under-served Populations:
Racial or Ethnic Minorities, Disadvantaged Circumstances, Limited English, Geographic Areas
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A